CIK细胞治疗恶性胸腔积液的临床研究  

Thoracic perfusion with CIK cells in the treatment of malignant pleural effusion:a clinical study

作　　者：熊锐华[1] 田秀荣[1] 伍靖武[1] 任庆[1] 李金燕[1] 曾丽莎[1] 张申众[2] 

机构地区：[1]中国人民解放军第一八一医院肿瘤治疗中心,桂林541002 [2]沈阳市胸科医院肿瘤科,沈阳110044

出　　处：《肿瘤》2010年第11期973-975,共3页Tumor

摘　　要：目的:探讨细胞因子诱导杀伤(cytokine induced killer,CIK)细胞胸腔内灌注治疗恶性胸腔积液的疗效。方法:对33例恶性胸腔积液患者行胸腔置管引流术及胸腔灌注治疗;所有患者随机分为2组:一组为胸腔灌注化疗组,顺铂(40 mg)联合氟尿嘧啶(0.75 g),每周2次,1~2周;另一组为CIK细胞胸腔灌注组,CIK细胞1×109个细胞/次,1次/d,连续灌注3 d。结果:CIK细胞胸腔灌注组患者的胸腔积液缓解疗效高于胸腔灌注化疗组,患者的生存质量、外周血白细胞计数均高于对照组。结论:采用CIK细胞行胸腔内灌注治疗晚期肿瘤患者的恶性胸腔积液疗效肯定,不良反应小,安全性好,能有效提高患者的生存质量,以争取获得进一步的治疗机会。Objective:To evaluate the efficacy of thoracic perfusion with cytokine induced killer(CIK) cells in the treatment of malignant pleural effusion.Methods:The thirty-three patients were given PICC implementation and thoracic infusion therapy.All the patients were randomly divided into 2 groups.For patients in control group 40 mg of cisplatin and 0.75 g of 5-FU were administered to the pleural cavities twice a week for 1 to 2 weeks.For patients in study group the CIK cells were transfused at 1×109 per dosage,once per day for 3 consecutive days.Results:Study group obtained better therapeutic efficacy in controlling the malignant pleural effusion.The living quality and the number of white blood cells in peripheral blood in study group was higher than those of control group.Conclusion:Thoracic perfusion with CIK cells was effective in the treatment of malignant pleural effusion in the patients with advanced tumor.It had better efficacy,mild adverse reaction,and good safety.It could effectively increase the living quality of the patients to obtain the opportunity for further treatment.

关 键 词：CIK细胞 胸腔灌注治疗 恶性胸腔积液 临床研究 malignant PLEURAL EFFUSION treatment cells 胸腔灌注化疗 晚期肿瘤患者 生存质量 血白细胞计数 胸腔内 细胞因子诱导 疗效肯定 置管引流术 连续灌注 氟尿嘧啶 不良反应 对照组 安全性 

分 类 号：R73[医药卫生—肿瘤]